WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014196916) SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT IN THE ORAL CAVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/196916    International Application No.:    PCT/SE2014/050670
Publication Date: 11.12.2014 International Filing Date: 02.06.2014
IPC:
A61K 9/36 (2006.01)
Applicants: MCNEIL AB [SE/SE]; Box 941 S-251 09 Helsingborg (SE)
Inventors: HUGERTH, Andreas; (SE).
LINDELL, Katarina; (SE).
NICKLASSON, Fredrik; (SE).
THYRESSON, Kristina; (SE)
Agent: ZACCO SWEDEN AB; P.O Box 5581 S-114 85 Stockholm (SE)
Priority Data:
1300404-9 03.06.2013 SE
Title (EN) SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT IN THE ORAL CAVITY
(FR) FORME DOSIFIÉE PHARMACEUTIQUE SOLIDE DE LIBÉRATION D'AU MOINS UN PRINCIPE PHARMACEUTIQUE ACTIF DANS LA CAVITÉ BUCCALE
Abstract: front page image
(EN)Solid pharmaceutical dosage form for the release of at least one Active Pharmaceutical Ingredient (API) in the oral cavity comprising a core coated by at least one film coating. The core comprises at least one API. One or more organoleptically disturbing sensations induced by one or several of the APIs and/or of inactive components of the solid pharmaceutical dosage form is/are reduced by constituents of said film coating. Said constituents comprise at least one film-forming polymer and at least one flavoring agent or at least one sweetener.
(FR)La présente invention concerne une forme dosifiée pharmaceutique solide de libération d'au moins un principe pharmaceutique actif (API) dans la cavité buccale, comprenant un noyau revêtu d'au moins un pelliculage. Le noyau comprend au moins un API. Des constituants dudit pelliculage réduisent une ou plusieurs sensations de perturbation organoleptique induites par un ou des API et/ou des composés inactifs de la forme dosifiée pharmaceutique solide. Lesdits constituants comprennent au moins un polymère de formation de pellicule et au moins un agent aromatisant ou au moins un édulcorant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)